

BOARD OF PHARMACY
Professional & Vocational Licensing Division
Department of Commerce and Consumer Affairs
State of Hawaii

MINUTES OF MEETING

Date: Thursday, October 17, 2013

Time: 9:00 a.m.

Place: King Kalakaua Conference Room
King Kalakaua Building
335 Merchant Street, First Floor
Honolulu, Hawaii 96813

Members Present: Todd Inafuku, Pharmacist
Mary Jo Keefe, Pharmacist
Lydia Kumasaka, Public Member
Garrett Lau, Pharmacist
Carolyn Ma, Pharmacist
Kerri Okamura, Pharmacist

Members Excused: Jill Oliveira Gray, Public Member

Staff Present: Lee Ann Teshima, Executive Officer ("EO")
Stephen Levins, Deputy Attorney General ("DAG")
Lisa Kalani, Secretary

Guests: Patrick Adams, Foodland
Jaclyn L. Moore, Foodland
Peter Whiticar, Department of Health ("DOH")
Luke Hasty, DOH
Tiffany Yajima, Ashford & Winston/Walgreens
Sean Chu
Albert Lau, Kaiser Permanente
Greg Edwards, DOH, Food and Drug Branch
Stacy Pi, Kaiser Permanente

Agenda: The agenda for this meeting was filed with the Office of the Lieutenant Governor, as required by section 92-7(b), Hawaii Revised Statutes ("HRS").

Call to Order: There being a quorum present, the Chair called the meeting to order at 9:00 a.m.

Announcements and Introductions

The Chair asked the audience to introduce themselves.

Additions/Additional Distribution to Agenda

The Chair called for a motion to add the following to the agenda:

Additions

7. Applications
 - b. Applications
 - 1) Miscellaneous Permit
 - iii. RX Pros Inc. dba Sterlington Village Pharmacy

Upon a motion by Ms. Kumasaka, seconded by Dr. Ma, it was voted on and unanimously carried to add the above mentioned application to the agenda.

The Chair announced that the following agenda item had additional distribution:

Additional Distribution

4. Correspondence
 - h. Concerns with Walgreens' Well Experience Pharmacy Model from Nell Geiser
 - Copies of correspondence between Walgreens and the Maryland Board of Pharmacy

Approval of the Previous Minutes – August 15, 2013

The Chair called for a motion in regards to the minutes of the August 15, 2013 meeting.

There being no amendments, upon a motion by Dr. Ma, seconded by Ms. Kumasaka, it was voted on and unanimously carried to approve the minutes for the August 15, 2013 meeting as circulated.

Executive Officer's Report:

Report on 2013 MPJE Item Pool Review

Mr. Lau reported on his attendance at the MPJE Item Pool Review he attended with Mark Brown.

He reported that there was a change in the review process this year, in addition to the standard areas of review, current approved items and pool and pretest item pool, the also conducted a pool reduction initiative. NABP assessed each jurisdiction's pool and evaluated the robustness of the competencies and the performance (statistics) of the items and from this assessment, a conservative number of items were recommended for removal, which did not risk the integrity of the State pool. He also reported that a total of 2,430 items were reviewed.

2014 Board of Pharmacy Meeting Schedule

The 2014 Board Meeting Schedule was distributed to the members for their information and the Chair recommended that the meeting dates for January and February 2014 be changed to the third week of the month so that the Board would have an opportunity to review/discuss any

proposed legislation which is scheduled to begin in the middle of January. This would allow the Board to provide testimony, if necessary, on bills introduced in the beginning of the session that are scheduled for hearing.

After some discussion, upon a motion by Ms. Keefe, seconded Ms. Okamura, it was voted on and unanimously carried to move the January and February 2014 meetings as follows:

January 23, 2014

February 13, 2014

Act 250, SLH 2013, Relating to Health (Expedited Partner Therapy)

The EO explained that the reason this was on the agenda again was to ensure that pharmacists understand the implications with this new law, specifically in regards to the prescription. Currently, Hawaii Administrative Rules §16-95-82 requires a valid prescription to include a patient's name, however, under the expedited partner therapy law, the prescription issued by the health care professional may not indicated an individual's name but state "Expedited Partner Therapy". She explained that because this is a "law" and the "valid prescription" section is included in the pharmacy administrative rules, the law would "trump" the admin rules.

The Chair stated that the Board was also being asked to assist the DOH in reviewing and making recommendations to the information sheet to be developed by the DOH and distributed to health professionals that include the following information pursuant to the new law:

1. A description of expedited partner therapy and its purpose;
2. A notice that an individual who has been treated for a sexually transmitted disease should be retested after treatment to detect possible persistent or recurrent infection, including information on the time of the retesting, as recommended by the Centers for Disease Control and Prevention;
3. A warning about the possible dangers of administering antibiotic therapy to a pregnant individual;
4. Information about antibiotics dispensed or prescribed and dosages of those antibiotics dispensed or prescribed, as recommended by the Centers for Disease Control and Prevention;
5. A warning about the risk of allergies to and drug interactions with the antibiotics described in paragraph (4);
6. Information about sexually transmitted diseases, the treatment of sexually transmitted diseases, and the prevention of sexually transmitted diseases;
7. A notice that the patient and the patient's partners should abstain from sexual activity for seven days after the patient and the partners have completed the antibiotic therapy;
8. A notice that the partners should be tested for sexually transmitted diseases;
9. A notice of the risk to the patient, the partners, and others, including the public health, if a sexually transmitted disease is not completely treated;
10. A notice of the responsibility of the patient to notify sexual partners of the risk of sexually transmitted diseases and the importance of examination and treatment for sexually transmitted diseases; and
11. A statement advising any individual who has any questions regarding anything in the information sheet to contact a health professional or the department of health.

The Board reviewed the draft of the information sheet provided by the DOH and the Chair recommended that

The Chair also stated that in the new law, pharmacists were included under the definition of "health professional", "Health professional" means any of the following:...For the purpose of dispensing antibiotic therapy under this section, a pharmacist who is licensed or otherwise authorized to engage in the practice of pharmacy under chapter 461... and would also be required to do all of the following:

1. Dispense or prescribe antibiotic therapy in the name of the partners, if known, without the physical examination of the partners by the health professional. Notwithstanding any law to the contrary, if the name of the partners are not known, the health professional shall dispense or prescribe the antibiotic therapy in the name of "Expedited Partner Therapy";
2. Convey to the patient that it is important to notify the patient's partners of the patient's diagnosis and that it is important for the partners to obtain medical care for a complete evaluation, testing for sexually transmitted diseases, counseling, and treatment;
3. Distribute to the patient the information sheet developed pursuant to section 453-C; and
4. Follow all Centers for Disease Control and Prevention guidelines related to the practices and recommendations for expedited partner therapy.

His concern is that pharmacists would need access to the information sheet developed by the DOH and recommended that after the information sheet is finalized, that it be posted on the Board's web page with a copy of the new law.

There being no further discussion, it was the consensus of the Board to accept the Chair's recommendations.

RICO Pharmacy Advisory Committee

The EO asked the members to review the list provided by RICO and if there were any recommendations.

There being none, upon a motion by Ms. Keefe, seconded by Ms. Kumasaka, it was voted on and unanimously carried to approve the RICO Pharmacy Advisory Committee list.

Correspondence:

National Association of Boards of Pharmacy (NABP)

Correspondence between DEA and NABP Regarding Controlled Substances Prescriptions with Missing DEA Number

The Board reviewed correspondence regarding information a pharmacist may provide when it is missing from a prescription for a schedule II controlled substance.

The correspondence will be referred to the Department of Health, Narcotics Enforcement Division for their information since it refers to controlled substances.

Request from the Mississippi Board of Pharmacy – Compounding for Physician Resale

The Board reviewed the following from the Mississippi Board of Pharmacy:

“Pharmacies are being asked to compound sterile preparations based on a patient-specific prescription and to sell those preparations to a physician. The physician would then resell the medication to a patient or bill their insurance, refill an implanted infusion pump in his or her office, and the pump would administer medication to the patient over a 30-180-day interval.

- Is the practice of compounding for resale permissible for pharmacies in your state? (yes or no)
- Is it a permissible practice in your state for a physician to obtain a controlled substance drug in this manner (yes or no)

After further discussion, it was the consensus of the Board to defer the first question to Mr. Edwards at the Department of Health, Food and Drug Branch to respond, and defer the second question to Department of Public Safety, Narcotics Enforcement Division to respond to the second question regarding controlled substances since they are the authority over Hawaii Revised Statutes Chapter 329, the Uniform Controlled Substances Act.

ACPE Grants International Pharmacy Program “Certification” (vs. “Accreditation”)

The Chair reported that at the August meeting, the Board was informed about the ACPE certification of King Saud University College of Pharmacy, the first international pharmacy degree program but wanted to clarify that the current pharmacy laws/rules refer to “accreditation” in regards to applicants for a pharmacist license and that ACPE’s “certification” process is distinct from program accreditation therefore, a graduate of an ACPE certified program would still have to meet the requirements of HRS §461-5 and HAR §16-95-22.

Questions regarding sale of syringes

The Board reviewed and discussed two emails regarding the sale/dispensing of syringes.

The first email inquiry from Jessica Bernheim, a pharmacy student/intern who is doing a project for one of her clinical rotations in which she is compiling a list of state laws regarding the dispensing of syringes, whether there is a quantity limit and if a prescription is required.

The second email inquiry from Laura Carpenter questioning whether a pharmacy permit is needed to sell insulin syringes directly to patients. Ms. Carpenter referred to the following Hawaii law which falls under the DOH:

“[§325-21] Sale of sterile syringes for the prevention of disease. (a) The sale of sterile hypodermic syringes in a pharmacy, physician's office, or health care institution for the purpose of preventing the transmission of dangerous blood-borne diseases, may be made solely by:

- (1) A pharmacist licensed under chapter 461;
- (2) A physician as defined in section 327E-2;
- (3) A health care provider as defined in section 327E-2; or

- (4) An authorized agent of a pharmacy, as defined in section 461-1, or of a health care institution, as defined in section 327E-2, operating under the direction of a licensed pharmacist or physician.
- (b) The seller under subsection (a) shall provide the purchaser written educational material approved by the department of health under subsection (e) about prevention of blood-borne diseases, drug treatment, and safe disposal of used syringes at sites where syringes are sold.
- (c) The sale or purchase of sterile hypodermic syringes under subsection (a) shall not constitute an offense under section 329-43.5.
- (d) Nothing in this section provides immunity from prosecution to any person who violates any law that prohibits or regulates the use, possession, dispensing, distribution, or promotion of controlled substances, dangerous drugs, detrimental drugs, or harmful drugs, including but not limited to violation of section 329-41, 329-42, or 712-1241 to 712-1249.6.
- (e) The department of health shall produce and make available to pharmacies, physicians' offices, and health care institutions written educational material about prevention of blood-borne diseases, drug treatment, and safe disposal of used syringes for distribution under subsection (b).
- (f) For purposes of this section, "sell" or "sale" means to transfer to another for value or consideration. [L 2001, c 292, §1; am L 2004, c 151, §2]"

There was discussion that insulin syringes may not need a prescription but other syringes may be labeled "on the order of a physician" and therefore a prescription or physician's order may be required for a pharmacy to "dispense" the syringe.

After further discussion it was the consensus of the Board that insulin syringes may not need a prescription to be sold, so that a pharmacy may sell this syringe, no quantity restrictions and without a prescription. However, the information regarding insulin syringes was not verified during the meeting, so if the label on the syringe requires a prescription or states "on the order of a physician", then it may be considered a medical device and a prescription or physician's order would be required in order for a pharmacy to "dispense" the syringe.

Furthermore, HRS §325 does allow physicians and other health providers to sell sterile syringes but they do not fall under the purview of the Board's laws and rules.

Pharmacy Compounding Academic Research – Volunteers?

The Board reviewed a request from Paul Oksesili, a graduate student at The George Washington University's System Engineering department who is looking for individuals to complete a survey about pharmacy compounding.

The EO asked the Board if they knew of anyone who met the criteria outlined by Mr. Oksesili regarding compounding experience.

Ms. Keefe volunteered to respond to Mr. Oksesili.

Prescriptions from Deceased Providers

The Board reviewed an email inquiry from Stacey Wathen of Healthcare Data Solutions asking what the protocol is for filling prescriptions from deceased providers.

The Chair stated that the Board previously addressed this issue after consulting with Mr. Edwards.

Mr. Edwards stated that he recalls that the Board determined the prescription may still be valid because at the time the prescription was issued, the physician was not deceased. The only issue would be if the pharmacist had any questions or needed authorization from the physician.

It was the consensus of the Board that the prescription is still valid even though the physician is deceased because the prescription was considered valid when initially issued by the physician. This informal interpretation applies to prescriptions for non-controlled substances only.

Manufactured Products from Non-Resident Pharmacies

The Board reviewed an email from Rachael Vardeman of Key Compounding Pharmacy asking the following questions on manufactured office use products.

After some discussion, it was the consensus of the Board to respond to Ms. Vardeman's questions as follows:

1. Are manufactured Office Used items allowed into Hawaii from Hawaii licensed Non-Resident pharmacies? *If the out-of-state entity is "dispensing" the drug into this State directly to the end user/patient pursuant to a valid prescription, then a Hawaii miscellaneous permit is required as an out-of-state pharmacy. If the out-of-state entity is "distributing" any prescription drug into this State to other than the end user/patient, then it is considered wholesale distribution and no license is required for out-of-state wholesale distributors.*
2. Does the shipping of manufactured items into Hawaii require a wholesaler license? If so, how do we apply if we decide to pursue it? *See response to question #1.*
3. Are there any other special requirements? *No.*

The above responses apply only to non-controlled substances.

Are Pharmacist Allowed to Administer Invega and Risperdal?

The Board reviewed an email inquiry asking if pharmacist were allowed to administer Invega and Risperdal and if the training was different than the standard immunization training.

Dr. Ma stated that at the August 15, 2013 meeting the Board had a presentation from Nancy Noe and Alen Wu of Johnson & Johnson regarding pharmacist participation in a program where a pharmacist would administer two specific psychotropic drugs in collaboration with a physician. Dr. Ma stated that the Board determined that pharmacists would be allowed to participate in this program limited to a physician's prescription and injection to the deltoid IM only by a pharmacist who received additional training.

There being no further discussion, it was the consensus of the Board that pharmacists may administer the psychotropic drugs Invega Sustenna and Risperdal Consta via injection to the deltoid IM if they received the additional training regarding the administration of the psychotropic drugs.

Concerns with Walgreens' Well Experience Pharmacy Model form Nell Geiser

The Board reviewed a report from Change to Win regarding concerns with Walgreen's "Well Experience" pharmacy model. The report has concerns with the pharmacy model that proposes to remove the pharmacists from the traditional production area of the pharmacy and placing them at a desk "out in front" of the counter. The pharmacist would remain responsible for the supervision of technicians as well as the final check of prescriptions via computer/video. Mr. Geiser expressed his concerns about risks to public health and patient privacy with this model.

The Board also reviewed copies of a letter submitted by Ms. Mariah Montgomery also of Change to Win, from the Maryland Board of Pharmacy that was sent to Walgreens explaining its position that the model did not provide adequate supervision.

After some discussion, it was the consensus of the Board to reaffirm their previous determination from their January 2013 meeting which was:

- The program presented must be in compliance with the pharmacy laws and rules, including but not limited to the pharmacist supervision of the pharmacy technician and other pharmacy personnel and the "initialing" of all prescriptions filled;
- Walgreens contact the Department of Public Safety, Narcotics Enforcement Division for compliance with HRS 329, the Uniform Controlled Substances Act;
- The Board accepts Walgreens offer to submit their policies and procedures for this program, not for Board approval but for informational purposes only;
- The Board be notified, in writing, of the implementation date for this program for Walgreens pharmacies located in this State; and
- Walgreens provide a status report 3-6 months after the implementation date on any issues, including comments from pharmacist working in this program in Hawaii.

Old Business:

HAR Title 16, Chapter 95 – Review of Draft #3 with Comments from EO

The EO stated that she has completed a draft of the justification sheet but wanted clarification on a couple of items pertaining to the night cabinet and the advertisement of prescription drugs.

Open Forum:

The Chair asked the audience if anyone was aware of any legislation pertaining to pharmacy for the 2014 Legislative Session.

Mr. Adams stated that he is thinking about legislation to delete the prescription requirement for pharmacists to administer the influenza vaccine to minors and that he would let the Board know.

Applications:

Ratification List

Upon a motion by Mr. Lau, seconded by Dr. Ma, it was voted on and unanimously carried to approve the attached ratification lists.

Executive Session: At 10:45 a.m., upon a motion by the Chair, seconded by Ms. Okamura, it was voted on and unanimously carried to move into executive session pursuant to §92-5(a)(1) and (4), HRS, "to consider and evaluate personal information relating to individuals applying for professional or vocational licenses cited in section 26-9 or both;" and "To consult with the Board's attorney on questions and issues pertaining to the board's powers, duties, privileges, immunities, and liabilities;".

At 11:23 a.m. upon a motion by Mr. Lau, seconded by Dr. Ma, it was voted on and unanimously carried to move out of executive session.

Applications:

Applications

Miscellaneous Permit

Upon a motion by Mr. Lau, seconded by Ms. Okamura, it was voted on and unanimously carried to approve the following application for miscellaneous permit license subject to receipt of license verifications for the pharmacy from Colorado, Alabama and Louisiana indicating the pharmacy licenses/permits are unencumbered:

AcariaHealth Pharmacy #11 Inc

Upon a motion by the Chair, seconded by Ms. Okamura, it was voted on and unanimously carried to approve the following application for a miscellaneous permit as an out-of-state pharmacy:

California Drug Compounding, LLC

Upon a motion by the Chair seconded by Ms. Okamura, it was voted on and unanimously carried to approve the following application with the condition that the approval does not include pharmacist Angela Hotard based on her prior disciplinary action by the Louisiana Board of Pharmacy pursuant to HRS §436B-19(7) & (12):

RX Pros Inc. dba Sterlington Village Pharmacy

Question Regarding Documentation of 1,500 Practical Experience Requirement

The Board reviewed a request asking if they would accept a paycheck or a letter from Human Resources to verify one's practical experience as she would prefer that her current employer not know that she is considering relocating.

The Board determined that they would not accept copies of paycheck stubs as proof of the practical experience but may accept a letter from Human Resources if it also includes a description of the job duties and responsibilities.

The EO explained that currently, proof of the practical experience is required in order to issue the license, not to take the NAPLEX or MPJE. So if this individual applied, and met the education requirement, she would be approved to sit for the Hawaii MPJE and upon passing would only have to submit proof of her practical experience and the license fees in order to obtain her Hawaii pharmacist license.

After some discussion, it was the consensus of the Board to inform the individual that she may apply for a Hawaii pharmacist license but that the proof of statement of practical experience is required for the issuance of the license.

Election of Board
Vice Chair:

The Chair called for nominations for the Vice Chair position. Mr. Lau was nominated by Dr. Ma, Ms. Kumasaka and Ms. Okamura. There being no further nominations, upon a motion by Ms. Kumasaka, seconded by Dr. Ma, it was voted on and unanimously carried to appoint Mr. Garrett Lau as the Board's Vice Chairperson.

Next Meeting:

The Chair announced the next Board meeting and asked if everyone was available.

Thursday, November 21, 2013
9:00 a.m.
King Kalakaua Conference Room
King Kalakaua Building, First Floor
335 Merchant Street
Honolulu, Hawaii 96813

Dr. Ma stated she will not be able to attend the November meeting.
Ms. Kumasaka stated that she was not sure if she can attend.

Adjournment:

With no further business to discuss, the Chair adjourned the meeting at 11:30 a.m.

Taken and recorded by:

Reviewed and approved by:

/s/ Lisa Kalani
Lisa Kalani, Secretary

/s/ Lee Ann Teshima
Lee Ann Teshima, Executive Officer

11/1/13

[] Minutes approved as is.

[X] Minutes approved with changes; see minutes of 11/21/13

BOARD OF PHARMACY

October 17, 2013 Ratification List

Miscellaneous Permits (PMP)

Change of PIC:

Foothills Professional Pharmacy Ltd. (PMP 789)

4545 E Chandler Blvd., Ste. 100

Phoenix, Arizona 85048

New PIC: Peter Petrov

Effective: 5/1/2013

Unique Pharmaceuticals (PMP 388)

5920 S. General Bruce Drive

Temple, Texas 76502

New PIC: Arthur Chaput

Effective: 7/31/2013

Southern Tier Home Infusion Inc. (PMP 821)

dba Pharmacy Innovations

2936 W 17th Street

Erie, Pennsylvania 16505

New PIC: Robert E. Buzas

Effective: 9/1/2013

Palm Beach Pharmaceuticals (PMP 513)

8409 N Military Trail

Palm Beach Gardens, Florida 33458

New PIC: Harrinarine Seegulam

Effective: 9/3/2013

Medco Health Solutions of Columbus West, Ltd. (PMP 321)

dba Medio Health

255 Phillippi Road

Columbus, Ohio 43228

New PIC: Joanne Colegrove

Effective: 8/14/2013

Express Scripts Specialty Distribution Services, Inc. (PMP 200)

8931 Springdale Avenue, Suite A

St. Louis, Missouri 63134

New PIC: Tara Wesselmann

Effective: 8/19/2013

Ameripharm (PMP 386)
dba MedVantx Pharmacy Services
2503 E 54th Street N
Sioux Falls, South Dakota 57104
New PIC: Christine Burg
Effective: 6/28/2013

CuraScript, Inc. (PMP 691)
dba CuraScript SP Specialty Pharmacy
2825 W Perimeter Road, Suite 112
Indianapolis, Indiana 46241
New PIC: Robyn Stewart
Effective: 8/30/2013

Medco Health Solution of Indiana, LLC (PMP 638)
4750 E. 450 S.
Whitestown, Indiana 46075
New PIC: Rhonda Yates
Effective: 8/31/2013

Prime Therapeutics Specialty Pharmacy LLC (PMP 774)
2354 Commerce Park Drive, Ste. 100
Orlando, Florida 32319
New PIC: Arijit Aichbhaumik
Effective: 6/25/2012

Name Change/Addition of TN or DBA:

Ameripharm (PMP 386)
dba MedVantx Pharmacy Services
2503 E 54th Street N
Sioux Falls, South Dakota 57104

A – Z Diabetes Care Club (PMP 837)
dba Rx Care Club
500 Eagles Landing Drive, Ste. B
Lakland, Florida 33810

Jaspreet Lalli (PMP 677)
dba CPP Pet Care
3250 Arden Road
Hayward, California 94545

Procure Pharmacy Director Inc. (PMP 195)
dba CVS Caremark #2921
105 Mall Blvd.
Monroeville, Pennsylvania 15146

Relocation and Name Change:

Walgreens Specialty Pharmacy LLC (PMP 669)
dba Walgreens Specialty Pharmacy #15443
10530 John W. Elliott Drive, Suite 100
Frisco, Texas 75033

Closure:

Great Lakes Medical Pharmacy (PMP 732)
dba BrightSky
23247 Pinewood St., #100
Warren, Michigan
Effective: 8/29/2013

RX Stat, Inc. (PMP 715)
4825 140th Avenue North
Clearwater, Florida 33764
Effective: 8/16/2013

Pharmacy (PHY)

Change of PIC:

Longs Drug Stores California LLC (PHY 740)
dba Longs Drugs #9952
4831 Kuhio Hwy., Ste. 500
Kapaa, Hawaii 96746
New PIC: Rachael Taira
Effective: 8/18/2013

Longs Drug Stores California LLC (PHY 735)
dba Longs Drugs #9259
94-060 Farrington Hwy., #6
Waipahu, Hawaii 96797
New PIC: Reid Inouye
Effective: 8/18/2013

Longs Drug Stores California LLC (PHY 733)
dba Longs Drugs #9249
75-5595 Palani Road
Kailua-Kona, Hawaii 96740
New PIC: Tasha Medeiros
Effective: 9/8/2013

Outrigger Shops, Ltd. (PHY 795)
dba Prince Kuhio Pharmacy II
1922 Kalakaua Avenue
Honolulu, Hawaii 96815
New PIC: Mia Takahashi
Effective: 8/30/2013

Outrigger Shop, Ltd. (PHY 200)

dba Kuhio Pharmacy

2330 Kuhio Avenue

Honolulu, Hawaii 96815

New PIC: Janelle Shin

Effective: 8/30/2013

Scripts Pharmacy Hawaii Incorporated (PHY 803)

15-2660 Keeau Pahoia Road, #205

Pahoia, Hawaii 96778

New PIC: Ismail Abdolahi

Effective: 9/11/2013

Kalihi-Palama Health Center (PHY 809)

dba KPHC Pharmacy II

952 N. King Street,

Honolulu, Hawaii 96817

New PIC: Teresa L. Chao

Effective 10/1/2012

Wal-Mart Stores Inc. (PHY 551)

dba Wal-Mart Pharmacy 10-2321

75-1015 Henry Street

Kailua-Kona, Hawaii 96740

New PIC: Joshua Moles

Effective: 9/14/2013

Safeway Inc. (PHY 453)

dba Safeway Pharmacy #1209

831 Kuhio Hwy

Kapaa, Hawaii 96746

New PIC: Ryan Trombley

Effective 4/25/2012

Safeway Inc. (PHY 823)

dba Safeway Pharmacy #2897

91-1119 Keanui Drive

Ewa Beach, Hawaii 96706

New PIC: David Hwang

Effective: 10/11/2013

Closure:

L.M. Martin Inc., dba Papalina Pharmacy (PHY 597)

4469 Papalina Road

Kalaheo, Hawaii 96741

Effective: 9/24/2013

LTYPE	LIC	NUM	BP	NAME	PART	1
PH		3536		RYAN W I	<	NISHIKAWA<
PH		3537		ANGELA W Y	<	LI<
PH		3538		KIMBERLY J	<	SMITH<
PH		3539		MALTE	<	BREITLOW<
PH		3540		SEAN NOBUHIRO	<	CHU<
PH		3541		MATHEW G	<	MULLAHY<
PH		3542		ANTHONY D T	<	TRAN<
PH		3543		KARA K	<	KANESHIRO<
PH		3544		MELISSA K	<	YONEDA<
PH		3545		SHITAL R	<	SHAH<
PH		3546		MATTHEW A	<	SASAKI<
PH		3547		BRENDAN F	<	KATAHARA<
PH		3548		JORDAN J	<	SHIBATA<
PH		3549		LAWRENCE E	<	MORRISON< II
PH		3550		SAMSON Y H	<	CHIK<
PH		3551		BRIDGET N	<	FRAZEE<
PH		3552		TORREY K	<	IKEDA<
PH		3553		AARON	<	LANI<
PH		3554		MARJAN	<	MOTTAGHI<
PH		3555		GARRET T	<	NAKATA<
PH		3556		HEATHER K	<	SAKAI<
PH		3557		IRVING R	<	VELLEUX<
PH		3558		REED D	<	VOLK<
PH		3559		JAMES D	<	HALL<
PH		3560		JASON A	<	OKAZAKI<
PH		3561		CHANEL K O	<	LUCAS<
PH		3562		LAURA A	<	ELIAS<
PH		3563		BRANDI L	<	MILLER<
PH		3564		ADRRYL	<	ADDISON<
PH		3565		MICHAEL S	<	TSUJI<
PH		3566		REECE K	<	UYENO<
PH		3567		ELLEN	<	CHENG<
PH		3568		MARJIE E	<	HEBERT<
PH		3569		RYAN K M	<	WONG<
PH		3570		DIANNE K T	<	FEIGENSPAN<
PH		3571		MARGARET P	<	KANG<
PH		3572		ALISON L	<	KOBAYASHI<
PH		3573		STEPHANIE K Y	<	LAM<
PH		3574		MICHAEL E	<	TAYLOR< JR
PH		3575		CHRISTOPHER S	<	AYSON<
PH		3576		RYAN C	<	GASPAR<
PH		3577		LORA ANN	<	MCCRAY<
PH		3578		CAITLIN M K	<	MIZOSHIRI<
PH		3579		LOREN M	<	SOTTO<
PH		3580		JEREMY K	<	NARCA<
PH		3581		GINA G	<	CHAN<
PH		3582		STACEY A	<	DWINAL<
PH		3583		DOUGLAS K	<	MCCAMPBELL<
PH		3584		ALLEN	<	SHIH<
PH		3585		SHANELE S	<	SHIMABUKU<
PH		3586		TANYA K	<	NOJIRI<
PH		3587		AARON K M	<	LEE<
PH		3588		MICHELLE-YEN	<	LE-FISHER<
PH		3589		LAUREN N	<	SUZUKI<
PH		3590		SANDRA K L	<	CHEE<
PH		3591		KATHLEEN M	<	KOKOSKI<
PH		3592		TIMOTHY J	<	RENER<

LTYPE	LIC NUM	BP NAME PART 1
PH	3593	LEMUEL B <PHIPPS<
PH	3594	COURTNEY H <INOUYE<

LTYPE TEMP LIC NUM VAM_BPR_LEGAL_NAME_1

PHI T130809003 DANIEL P <BURGOS<
PHI T130813001 HARSKIN <HAYES<
PHI T130809002 BRITTANY D <BISSELL<
PHI T130916001 MATTHEW L <DOHMAN<
PHI T130809001 JENNIFER J <NAM<
PHI T130916002 LEAH J <MILLER<
PHI T130819001 RYAN L <MALCOM<
PHI T130823003 CELESTI M <MAGPAYO<
PHI T130823001 JESSIE <HORI<
PHI T130823002 MICHAEL L <MARTINEZ<
PHI T130730003 AMANDA D <POWELL<
PHI T130916003 CHRISTINA <SZETO<

LTYPE	LIC NUM	LIC NAME PART 1	BUSN ADDR 1	BUSN CITY	BUSN		
					ST	BUSN ZIP	BP NAME PART 1
PHY	843	SFEWAY PHARMACY #3092	58 MAUI LANI PKWY	WAILUKU	HI	96793	SAFEWAY INC
PHY	844		KAISER KAPOLEI PHARMACY	KAPOLEI	HI	96707	KAISER FOUNDATION HEALTH PLAN INC

LTYPE	LIC NUM	LIC NAME PART 1	BUSN ADDR 1	BUSN CITY	BUSN		
					ST	BUSN ZIP	BP NAME PART 1
PMP	865		5169 BRUNSWICK RD BOX 305	BRUNSWICK	TN	38014	RESTORE RX INC
PMP	866		6580 SNOWDRIFT RD STE 100	ALLENTOWN	PA	18106	CENTRAL ADMIXTURE PHARMACY SERVICE
PMP	867		4 NESHAMINY INTERPLEX DR #111	TREVOSE	PA	19053	TRANSITION PHARMACY LLC
PMP	868	CURASCRIPT SP SPECIALTY PHARMACY	5653 STONERIDGE STE 109	PLEASANTON	CA	94588	CURASCRIPT INC
PMP	869	WESTCLIFF COMPOUNDING PHARMACY	1901 WESTCLIFF DR #3	NEWPORT BEACH	CA	92660	PROFESSIONAL PARTNERS INC
PMP	870		345 INTERNATIONAL BLVD STE 200	BROOKS	KY	40109	IHS ACQUISITION XXX INC
PMP	871		3302 GARFIELD AVE	COMMERCE	CA	90040	ACARIAHEALTH PHARMACY #13 INC
PMP	872	CVS CAREMARK	1780 WALL ST	MT PROSPECT	IL	60056	CVS CAREMARK ADVANCED TECHNOLOGY P
PMP	873		102 N BROADWAY	SKIATOOK	OK	74070	OK COMPOUNDING LLC
PMP	874		440 W BROADWAY STE B	GLENDALE	CA	91204	KVP PHARMACY INC
PMP	875		1130 N NIMITZ HWY #A153A1B	HONOLULU	HI	96817	OPEN DOOR RX INC
PMP	876		2288 AUBURN BLVD STE 102	SACRAMENTO	CA	95821	AVELLA OF SACRAMENTO INC
PMP	877		330 S WARMINSTER RD STE 350	HATBORO	PA	19040	PHILIDOR RX SERVICES LLC
PMP	878		1519 HWY 22W	MADISONVILLE	LA	70447	WILLOW PHARMACY
PMP	879		3200 S POLARIS AVE #27	LAS VEGAS	NV	89102	MEDITECH LABORATORIES INC
PMP	880		4079 PEMBERTON BLVD	VICKSBURG	MS	39180	VICKSBURG SPECIAL CARE PHARMACY AN
PMP	881		1819 ASTON AVE STE 102	CARLSBAD	CA	92008	BIORX LLC
PMP	882		14905 ANSLEY CT	MORENO VALLEY	CA	92555	INLAND MEDICAL CONSULTANTS LLC
PMP	883		1710 N SHELBY OAKS DR STE 1	MEMPHIS	TN	38134	ANOVORX GROUP LLC